“New Standard of Care”? Lung Cancer KOLs on KRASCENDO-1 and ESMO26
ESMO26 lung KOL reactions: KRASCENDO-1 OS HR 0.56, PERSEE PFS HR 0.56, DeLLphi-305 OS HR 0.42, and four China-only ADC trials in NSCLC.
ESMO 2026: Oncology is the Tip of the Spear for AI in Healthcare
ESMO 2026: oncology leads OpenEvidence use (JAMA), and digital opinion leaders moved INTerpath-001, NADINA and KRASCENDO-1 debates at X speed.
ESMO 2026 Day 3: Top Trials and KOL Reactions
ESMO 2026 Day 3: KRASCENDO-1 and the crossover question, SAFFRON, HARMONi-GI1, CLARITY-Gastric01, PERSEE, LITESPARK-012, NADINA and more, with physician reactio…
ESMO 2026: Top Melanoma Trials and KOL Voices
ESMO 2026 Madrid melanoma, October 23–26: investigational INTerpath-001 led physician discussion, followed by the NADINA 3-year update, STARBOARD and TIL data, …
ESMO 2026: Top GI Cancer Trials and KOL Voices
ESMO 2026 Madrid GI cancers, October 23–26: HARMONi-GI1, CLARITY-Gastric01, HERIZON-GEA-01, SANO, G-HOPE-001, IROCAS and AZUR-1, with verbatim physician reactio…
ESMO 2026: Top Gynecologic Cancer Trials and KOL Voices
ESMO 2026 Madrid gynecologic cancers, October 23–26: TroFuse-005 and KEYNOTE-C93 from Presidential Symposium III, plus NRG-GY020, DUO-E and BEHOLD-1, with verba…
ESMO 2026: Top Breast Cancer Trials and KOL Voices
ESMO 2026 Madrid breast cancer, October 23–26: NATALEE, KEYNOTE-B49, PANKU-Breast01, FOURLIGHT-1, SWITCH, BRIDGET, OptiTROP-Breast01 and DESTINY-Breast09, with …
ESMO 2026: Top Lung Cancer Trials and KOL Voices
ESMO 2026 Madrid lung cancer, October 23–26: DeLLphi-305, KRASCENDO-1, SAFFRON, PERSEE, OptiTROP-Lung06, PANKU-Lung01 and HERON-Lung01, with verbatim physician …
ESMO 2026: Top GU Cancer Trials and KOL Voices
ESMO 2026 Madrid GU cancers, October 23–26: VOLGA, KEYNOTE-866, DASL-HiCaP, LITESPARK-012 and TALAPRO-3, FDA approved October 26, with verbatim physician reacti…
ESMO 2026 Days 1–2: Top Trials and KOL Reactions
ESMO 2026 Days 1-2: a standing ovation for DeLLphi-305 and the crossover question physicians raised, plus INTerpath-001, VOLGA, NATALEE, PANKU-Breast01 and more…
The ESMO 2026 Debates from the KOL Social Media Threads
ESMO 2026 physician debates on X, verbatim: INTerpath-001 vs neoadjuvant IO, NATALEE's nominal OS p-value, me-too HER2 ADCs, pCR vs EFS in bladder cancer, KEYNO…
ENERGIZE and KEYNOTE-866: Two Negative Phase 3 MIBC Trials at ESMO 2026, and the NIAGARA Question
ESMO 2026: perioperative nivolumab (ENERGIZE, EFS HR 0.94) and pembrolizumab (KEYNOTE-866, EFS HR 0.88, OS HR 1.00) with gem/cis did not improve EFS in cisplati…
The INTerpath-001 Leak: An Embargo Break, a 25% Drop, and What Oncologists Said
ESMO lifted the LBA1 embargo after INTerpath-001 results leaked early: RFS HR 0.58 (95% CI 0.45–0.75). Moderna fell 25%. What oncologists and investors said.
PATINA Trial - Dr. Olivier Told You So!!!
Feb: Timothée Olivier, MD, flagged PATINA's open-label, investigator-assessed PFS. Jun: FDA approval. Oct: EMA says benefits “had not been demonstrated.”
“More Market Than Medical” — The Oncologists Doubting Galleri as the FDA Panel Meets
FDA's first MCED advisory panel meets Sept 23 as NEJM publishes NHS-Galleri's missed primary endpoint (stage III/IV IRR 1.03). Verbatim skepticism from Drs. Bur…
Etcamah (Camizestrant) Is FDA Approved — and Some KOLs Still Agree With ODAC's No Vote
SERENA-6 KOL sentiment after the Etcamah (camizestrant) FDA approval: Tatiana Prowell, Angela DeMichele's ASCO plenary takeaways, Gyawali and other voices who s…
The DOL Launch: How Digital Opinion Leaders Ran Rasonque's Day One Product Launch
How KOLs and DOLs ran their own product launch for Rasonque (daraxonrasib) in pancreatic cancer: sequencing, patient selection, biomarkers, and patient educatio…
Key Learnings from COSMO 2026 for Digital Opinion Leaders and Patient Advocates
What the COSMO 2026 faculty slides teach oncology's digital voices and patient advocates: misinformation rates by platform, who patients trust, AI chatbot quali…
Gedatolisib (Revtorpyk) Is FDA Approved: What Breast Oncology KOLs Said on Day One
What breast oncology KOLs said within hours of the gedatolisib (Revtorpyk) FDA approval: doublet vs triplet, weekly-IV burden, and the 2.0-month control arm.